<p>Fennec Pharmaceuticals Inc.（TSE:FRX - 獲取免費報告）高級官員羅伯特·克里斯托弗·安德拉德於 6 月 2 日星期一購買了 8,220 股該公司的股票。每股的平均購買成本為 6.99 加元，總交易額為 57,433.14 加元。</p>
<p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
<h2>Fennec Pharmaceuticals 股價上漲 1.5%</h2>
<p>FRX 股票在週三的午盤交易中上漲了 0.17 加元，達到 11.33 加元。該股票成交 136 股，成交量低於其平均成交量 1,205 股。該股票的 50 日移動平均線為 8.64 加元，200 日移動平均線為 8.81 加元。該公司的市值為 2.185 億加元，市盈率為-191.93，貝塔值為 0.25。Fennec Pharmaceuticals Inc. 的 52 周低點為 5.65 加元，52 周高點為 11.68 加元。該公司的流動比率為 7.80，速動比率為 10.17，負債權益比為-620.83。</p>
<h2>關於 Fennec Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Fennec Pharmaceuticals Inc. 是一家在美國運營的生物製藥公司。該公司的產品候選包括 PEDMARK，一種用於預防鉑類藥物引起的兒童癌症患者耳毒性的硫代硫酸鈉製劑。它通過區域兒童腫瘤學專家和醫學科學聯絡員銷售其產品。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Fennec Pharmaceuticals</li>
<li>黃金交叉股票：模式、示例和圖表</li>
<li>Guidewire 大幅上漲：超過 300 美元的可能性</li>
<li>如何捕捉股息增加的好處</li>
<li>模擬器件的週期性復甦故事剛剛開始</li>
<li>3 只股票引領迷因股復興</li>
<li>Joby 與沙特的諒解備忘錄：強勁的初步反應遇到市場動態</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Fennec Pharmaceuticals 嗎？</h2>
<p>在考慮 Fennec Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Fennec Pharmaceuticals 並不在名單上。</p>
<p>雖然 Fennec Pharmaceuticals 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

FENC

<p>羅伯特·克里斯托弗·安德拉德（Robert Christopher Andrade），Fennec Pharmaceuticals Inc.（TSE:FRX）的高級官員，於 6 月 2 日以每股平均 6.99 加元的價格購買了 8,220 股公司股票，總計 57,433.14 加元。在此交易之後，Fennec 的股票上漲了 1.5%，達到了 11.33 加元。該公司的市值為 2.185 億加元，市盈率為-191.93。Fennec Pharmaceuticals 專注於生物製藥，特別是在兒童腫瘤學領域</p>

<p>Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) Senior Officer Robert Christopher Andrade bought 8,220 shares of the company's stock in a transaction on Monday, June 2nd. The stock was bought at an average cost of C$6.99 per share, for a total transaction of C$57,433.14.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.（TSE:FRX - 獲取免費報告）高級官員羅伯特·克里斯托弗·安德拉德於 6 月 2 日星期一購買了 8,220 股該公司的股票。每股的平均購買成本為 6.99 加元，總交易額為 57,433.14 加元。</p>
</div><p>Get <strong>Fennec Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Fennec Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Fennec Pharmaceuticals Trading Up 1.5%</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals 股價上漲 1.5%</h2>
</div><p>FRX stock traded up C$0.17 during mid-day trading on Wednesday, reaching C$11.33. 136 shares of the stock traded hands, compared to its average volume of 1,205. The stock's fifty day moving average is C$8.64 and its 200-day moving average is C$8.81. The company has a market cap of C$218.50 million, a P/E ratio of -191.93 and a beta of 0.25. Fennec Pharmaceuticals Inc. has a 52-week low of C$5.65 and a 52-week high of C$11.68. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.</p>
<div class="lb-trans"><p>FRX 股票在週三的午盤交易中上漲了 0.17 加元，達到 11.33 加元。該股票成交 136 股，成交量低於其平均成交量 1,205 股。該股票的 50 日移動平均線為 8.64 加元，200 日移動平均線為 8.81 加元。該公司的市值為 2.185 億加元，市盈率為-191.93，貝塔值為 0.25。Fennec Pharmaceuticals Inc. 的 52 周低點為 5.65 加元，52 周高點為 11.68 加元。該公司的流動比率為 7.80，速動比率為 10.17，負債權益比為-620.83。</p>
</div><h2>About Fennec Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Fennec Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc. 是一家在美國運營的生物製藥公司。該公司的產品候選包括 PEDMARK，一種用於預防鉑類藥物引起的兒童癌症患者耳毒性的硫代硫酸鈉製劑。它通過區域兒童腫瘤學專家和醫學科學聯絡員銷售其產品。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Fennec Pharmaceuticals</li>
<li>Golden Cross Stocks: Pattern, Examples and Charts</li>
<li>Guidewire Rockets Higher: A Move Above $300 Is Probable</li>
<li>How to Capture the Benefits of Dividend Increases</li>
<li>Analog Devices' Cyclical Recovery Story Has Just Begun</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Joby's Saudi MoU: Strong Initial Reaction Meets Market Dynamics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Fennec Pharmaceuticals</li>
<li>黃金交叉股票：模式、示例和圖表</li>
<li>Guidewire 大幅上漲：超過 300 美元的可能性</li>
<li>如何捕捉股息增加的好處</li>
<li>模擬器件的週期性復甦故事剛剛開始</li>
<li>3 只股票引領迷因股復興</li>
<li>Joby 與沙特的諒解備忘錄：強勁的初步反應遇到市場動態</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9RlJY" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=TSE&amp;Symbol=FRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fennec Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Fennec Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Fennec Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Fennec Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Fennec Pharmaceuticals 並不在名單上。</p>
</div><p>While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Fennec Pharmaceuticals 目前在分析師中獲得了強烈買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

羅伯特·克里斯托弗·安德拉德購入了 8,220 股 Fennec Pharma（TSE:FRX）的股票